#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-2	In	_
1-2	3-10	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-3	11-21	dependence	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
1-4	22-23	,	_
1-5	24-30	neural	_
1-6	31-41	prediction	_
1-7	42-48	errors	_
1-8	49-55	during	_
1-9	56-60	loss	_
1-10	61-70	avoidance	_
1-11	71-74	are	_
1-12	75-84	increased	_
1-13	85-89	with	_
1-14	90-97	cocaine	_
1-15	98-109	deprivation	_
1-16	110-113	and	_
1-17	114-121	predict	_
1-18	122-126	drug	_
1-19	127-130	use	_
1-20	131-141	Background	_
1-21	142-143	:	_
1-22	144-146	In	_
1-23	147-156	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
1-24	157-166	dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
1-25	167-178	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
1-26	179-180	,	_
1-27	181-197	drug-deprivation	_
1-28	198-201	and	_
1-29	202-210	drug-use	_
1-30	211-218	trigger	_
1-31	219-228	divergent	_
1-32	229-239	behavioral	_
1-33	240-249	responses	_
1-34	250-252	to	_
1-35	253-266	environmental	_
1-36	267-271	cues	_
1-37	272-273	.	_

2-1	274-279	These	_
2-2	280-289	divergent	_
2-3	290-299	responses	_
2-4	300-303	are	_
2-5	304-313	consonant	_
2-6	314-318	with	_
2-7	319-323	data	_
2-8	324-331	showing	_
2-9	332-336	that	_
2-10	337-343	short-	_
2-11	344-347	and	_
2-12	348-357	long-term	_
2-13	358-369	adaptations	_
2-14	370-372	in	_
2-15	373-381	dopamine	_
2-16	382-391	signaling	_
2-17	392-395	are	_
2-18	396-405	similarly	_
2-19	406-415	sensitive	_
2-20	416-418	to	_
2-21	419-424	state	_
2-22	425-427	of	_
2-23	428-436	drug-use	_
2-24	437-438	.	_

3-1	439-444	These	_
3-2	445-456	literatures	_
3-3	457-464	suggest	_
3-4	465-466	a	_
3-5	467-477	drug-state	_
3-6	478-487	dependent	_
3-7	488-492	role	_
3-8	493-495	of	_
3-9	496-504	learning	_
3-10	505-507	in	_
3-11	508-519	maintaining	_
3-12	520-529	substance	_
3-13	530-533	use	_
3-14	534-535	;	_
3-15	536-544	evidence	_
3-16	545-552	linking	_
3-17	553-561	dopamine	_
3-18	562-564	to	_
3-19	565-569	both	_
3-20	570-583	reinforcement	_
3-21	584-592	learning	_
3-22	593-596	and	_
3-23	597-606	addiction	_
3-24	607-615	provides	_
3-25	616-617	a	_
3-26	618-627	framework	_
3-27	628-630	to	_
3-28	631-635	test	_
3-29	636-640	this	_
3-30	641-652	possibility	_
3-31	653-654	.	_

4-1	655-662	Methods	_
4-2	663-664	:	_
4-3	665-667	In	_
4-4	668-669	a	_
4-5	670-680	randomized	_
4-6	681-690	crossover	_
4-7	691-697	design	_
4-8	698-699	,	_
4-9	700-702	22	_
4-10	703-715	participants	_
4-11	716-720	with	http://maven.renci.org/NeuroBridge/neurobridge#MethylenedioxymethamphetamineDependence
4-12	721-728	current	http://maven.renci.org/NeuroBridge/neurobridge#MethylenedioxymethamphetamineDependence
4-13	729-736	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
4-14	737-740	use	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
4-15	741-749	disorder	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
4-16	750-759	completed	_
4-17	760-761	a	_
4-18	762-775	probabilistic	_
4-19	776-789	loss-learning	http://maven.renci.org/NeuroBridge/neurobridge#II
4-20	790-794	task	http://maven.renci.org/NeuroBridge/neurobridge#II
4-21	795-801	during	_
4-22	802-812	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-23	813-816	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
4-24	817-822	while	_
4-25	823-826	on-	_
4-26	827-830	and	_
4-27	831-842	off-cocaine	_
4-28	843-844	(	_
4-29	845-847	44	_
4-30	848-856	sessions	_
4-31	857-858	)	_
4-32	859-860	.	_

5-1	861-863	54	_
5-2	864-876	participants	_
5-3	877-884	without	_
5-4	885-891	Axis-I	_
5-5	892-907	psychopathology	_
5-6	908-914	served	_
5-7	915-917	as	_
5-8	918-919	a	_
5-9	920-929	secondary	_
5-10	930-939	reference	_
5-11	940-945	group	_
5-12	946-947	.	_

6-1	948-959	Within-drug	_
6-2	960-965	state	_
6-3	966-969	and	_
6-4	970-985	paired-subjects	_
6-5	986-987	’	_
6-6	988-996	learning	_
6-7	997-1004	effects	_
6-8	1005-1009	were	_
6-9	1010-1018	assessed	_
6-10	1019-1023	with	_
6-11	1024-1043	computational-model	_
6-12	1044-1051	derived	_
6-13	1052-1062	individual	_
6-14	1063-1071	learning	_
6-15	1072-1082	parameters	_
6-16	1083-1084	.	_

7-1	1085-1096	Model-based	_
7-2	1097-1109	neuroimaging	_
7-3	1110-1118	analyses	_
7-4	1119-1128	evaluated	_
7-5	1129-1136	effects	_
7-6	1137-1139	of	_
7-7	1140-1148	drug-use	_
7-8	1149-1154	state	_
7-9	1155-1157	on	_
7-10	1158-1164	neural	_
7-11	1165-1173	learning	_
7-12	1174-1181	signals	_
7-13	1182-1183	.	_

8-1	1184-1197	Relationships	_
8-2	1198-1203	among	_
8-3	1204-1217	model-derived	_
8-4	1218-1228	behavioral	_
8-5	1229-1237	learning	_
8-6	1238-1243	rates	_
8-7	1244-1245	(	_
8-8	1246-1248	α+	_
8-9	1249-1250	,	_
8-10	1251-1253	α-	_
8-11	1254-1255	)	_
8-12	1256-1257	,	_
8-13	1258-1264	neural	_
8-14	1265-1275	prediction	_
8-15	1276-1281	error	_
8-16	1282-1289	signals	_
8-17	1290-1291	(	_
8-18	1292-1294	δ+	_
8-19	1295-1296	,	_
8-20	1297-1299	δ-	_
8-21	1300-1301	)	_
8-22	1302-1303	,	_
8-23	1304-1311	cocaine	_
8-24	1312-1315	use	_
8-25	1316-1317	,	_
8-26	1318-1321	and	_
8-27	1322-1328	desire	_
8-28	1329-1331	to	_
8-29	1332-1335	use	_
8-30	1336-1340	were	_
8-31	1341-1349	assessed	_
8-32	1350-1351	.	_

9-1	1352-1359	Results	_
9-2	1360-1361	:	_
9-3	1362-1368	During	_
9-4	1369-1388	cocaine-deprivation	_
9-5	1389-1390	,	_
9-6	1391-1398	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
9-7	1399-1408	dependent	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
9-8	1409-1420	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
9-9	1421-1430	exhibited	_
9-10	1431-1441	heightened	_
9-11	1442-1450	positive	_
9-12	1451-1459	learning	_
9-13	1460-1465	rates	_
9-14	1466-1467	(	_
9-15	1468-1470	α+	_
9-16	1471-1472	)	_
9-17	1473-1474	,	_
9-18	1475-1485	heightened	_
9-19	1486-1492	neural	_
9-20	1493-1501	positive	_
9-21	1502-1512	prediction	_
9-22	1513-1518	error	_
9-23	1519-1520	(	_
9-24	1521-1523	δ+	_
9-25	1524-1525	)	_
9-26	1526-1535	responses	_
9-27	1536-1537	,	_
9-28	1538-1541	and	_
9-29	1542-1552	heightened	_
9-30	1553-1564	association	_
9-31	1565-1567	of	_
9-32	1568-1570	α+	_
9-33	1571-1575	with	_
9-34	1576-1582	neural	_
9-35	1583-1585	δ+	_
9-36	1586-1595	responses	_
9-37	1596-1597	.	_

10-1	1598-1601	The	_
10-2	1602-1622	deprivation-enhanced	_
10-3	1623-1629	neural	_
10-4	1630-1638	learning	_
10-5	1639-1646	signals	_
10-6	1647-1651	were	_
10-7	1652-1660	specific	_
10-8	1661-1663	to	_
10-9	1664-1674	successful	_
10-10	1675-1679	loss	_
10-11	1680-1689	avoidance	_
10-12	1690-1691	,	_
10-13	1692-1702	comparable	_
10-14	1703-1705	to	_
10-15	1706-1721	non-psychiatric	_
10-16	1722-1734	participants	_
10-17	1735-1736	,	_
10-18	1737-1740	and	_
10-19	1741-1749	mediated	_
10-20	1750-1751	a	_
10-21	1752-1764	relationship	_
10-22	1765-1772	between	_
10-23	1773-1783	chronicity	_
10-24	1784-1786	of	_
10-25	1787-1791	drug	_
10-26	1792-1795	use	_
10-27	1796-1799	and	_
10-28	1800-1806	desire	_
10-29	1807-1809	to	_
10-30	1810-1813	use	_
10-31	1814-1821	cocaine	_
10-32	1822-1823	.	_

11-1	1824-1835	Conclusions	_
11-2	1836-1837	:	_
11-3	1838-1856	Neurocomputational	_
11-4	1857-1865	learning	_
11-5	1866-1873	signals	_
11-6	1874-1877	are	_
11-7	1878-1887	sensitive	_
11-8	1888-1890	to	_
11-9	1891-1899	drug-use	_
11-10	1900-1906	status	_
11-11	1907-1910	and	_
11-12	1911-1918	suggest	_
11-13	1919-1923	that	_
11-14	1924-1934	heightened	_
11-15	1935-1948	reinforcement	_
11-16	1949-1951	by	_
11-17	1952-1962	successful	_
11-18	1963-1972	avoidance	_
11-19	1973-1975	of	_
11-20	1976-1984	negative	_
11-21	1985-1993	outcomes	_
11-22	1994-1997	may	_
11-23	1998-2008	contribute	_
11-24	2009-2011	to	_
11-25	2012-2016	drug	_
11-26	2017-2024	seeking	_
11-27	2025-2031	during	_
11-28	2032-2043	deprivation	_
11-29	2044-2045	.	_

12-1	2046-2050	More	_
12-2	2051-2060	generally	_
12-3	2061-2062	,	_
12-4	2063-2072	attention	_
12-5	2073-2075	to	_
12-6	2076-2084	drug-use	_
12-7	2085-2090	state	_
12-8	2091-2093	is	_
12-9	2094-2103	important	_
12-10	2104-2107	for	_
12-11	2108-2119	delineating	_
12-12	2120-2130	substrates	_
12-13	2131-2133	of	_
12-14	2134-2143	addiction	_
12-15	2144-2145	.	_

13-1	2146-2153	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-2	2154-2157	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-3	2158-2167	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
13-4	2168-2180	Participants	_
13-5	2181-2184	and	_
13-6	2185-2197	Experimental	_
13-7	2198-2204	Design	http://maven.renci.org/NeuroBridge/neurobridge#StudyDesign
13-8	2205-2215	Twenty-two	_
13-9	2216-2221	right	_
13-10	2222-2228	handed	_
13-11	2229-2230	,	_
13-12	2231-2244	non-treatment	_
13-13	2245-2252	seeking	_
13-14	2253-2257	male	_
13-15	2258-2269	individuals	_
13-16	2270-2273	who	_
13-17	2274-2277	met	_
13-18	2278-2286	criteria	_
13-19	2287-2291	only	_
13-20	2292-2295	for	_
13-21	2296-2303	current	_
13-22	2304-2311	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
13-23	2312-2315	use	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
13-24	2316-2324	disorder	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse
13-25	2325-2332	without	_
13-26	2333-2338	other	_
13-27	2339-2348	substance	_
13-28	2349-2361	dependencies	_
13-29	2362-2364	or	_
13-30	2365-2373	comorbid	_
13-31	2374-2380	Axis-I	_
13-32	2381-2396	psychopathology	_
13-33	2397-2401	were	_
13-34	2402-2410	enrolled	_
13-35	2411-2415	from	_
13-36	2416-2417	a	_
13-37	2418-2424	larger	_
13-38	2425-2430	study	_
13-39	2431-2433	on	_
13-40	2434-2444	biomarkers	_
13-41	2445-2447	of	_
13-42	2448-2457	substance	_
13-43	2458-2461	use	_
13-44	2462-2463	(	_
13-45	2464-2467	see	_
13-46	2468-2473	Table	_
13-47	2474-2475	1	_
13-48	2476-2479	for	_
13-49	2480-2491	demographic	_
13-50	2492-2503	information	_
13-51	2504-2507	and	_
13-52	2508-2520	Supplemental	_
13-53	2521-2528	Methods	_
13-54	2529-2532	for	_
13-55	2533-2552	inclusion/exclusion	_
13-56	2553-2561	criteria	_
13-57	2562-2563	)	_
13-58	2564-2565	.	_

14-1	2566-2575	Following	_
14-2	2576-2578	an	_
14-3	2579-2586	initial	_
14-4	2587-2590	lab	_
14-5	2591-2596	visit	_
14-6	2597-2599	to	_
14-7	2600-2606	assess	_
14-8	2607-2614	cocaine	_
14-9	2615-2618	use	_
14-10	2619-2622	and	_
14-11	2623-2631	entrance	_
14-12	2632-2640	criteria	_
14-13	2641-2642	,	_
14-14	2643-2651	eligible	_
14-15	2652-2663	individuals	_
14-16	2664-2676	participated	_
14-17	2677-2679	in	_
14-18	2680-2683	two	_
14-19	2684-2694	subsequent	_
14-20	2695-2703	scanning	_
14-21	2704-2712	sessions	_
14-22	2713-2715	in	_
14-23	2716-2717	a	_
14-24	2718-2732	within-subject	_
14-25	2733-2739	design	_
14-26	2740-2741	:	_
14-27	2742-2744	In	_
14-28	2745-2748	one	_
14-29	2749-2756	session	_
14-30	2757-2758	,	_
14-31	2759-2771	participants	_
14-32	2772-2776	were	_
14-33	2777-2787	instructed	_
14-34	2788-2790	to	_
14-35	2791-2794	use	_
14-36	2795-2802	cocaine	_
14-37	2803-2805	as	_
14-38	2806-2811	usual	_
14-39	2812-2813	(	_
14-40	2814-2816	C+	_
14-41	2817-2818	)	_
14-42	2819-2820	,	_
14-43	2821-2824	and	_
14-44	2825-2827	in	_
14-45	2828-2829	a	_
14-46	2830-2836	second	_
14-47	2837-2844	session	_
14-48	2845-2846	,	_
14-49	2847-2859	participants	_
14-50	2860-2864	were	_
14-51	2865-2875	instructed	_
14-52	2876-2878	to	_
14-53	2879-2886	abstain	_
14-54	2887-2891	from	_
14-55	2892-2899	cocaine	_
14-56	2900-2903	use	_
14-57	2904-2907	for	_
14-58	2908-2910	at	_
14-59	2911-2916	least	_
14-60	2917-2919	72	_
14-61	2920-2925	hours	_
14-62	2926-2927	(	_
14-63	2928-2930	C-	_
14-64	2931-2932	)	_
14-65	2933-2934	.	_

15-1	2935-2946	Cocaine-use	_
15-2	2947-2952	state	_
15-3	2953-2956	was	_
15-4	2957-2965	verified	_
15-5	2966-2968	at	_
15-6	2969-2973	each	_
15-7	2974-2977	lab	_
15-8	2978-2983	visit	_
15-9	2984-2988	with	_
15-10	2989-2994	urine	_
15-11	2995-3002	testing	_
15-12	3003-3006	for	_
15-13	3007-3014	cocaine	_
15-14	3015-3026	metabolites	_
15-15	3027-3028	(	_
15-16	3029-3033	NIDA	_
15-17	3034-3041	5-panel	_
15-18	3042-3046	drug	_
15-19	3047-3051	test	_
15-20	3052-3053	;	_
15-21	3054-3059	Alere	_
15-22	3060-3061	,	_
15-23	3062-3066	Inc.	_
15-24	3067-3068	)	_
15-25	3069-3070	;	_
15-26	3071-3073	C+	_
15-27	3074-3077	and	_
15-28	3078-3080	C-	_
15-29	3081-3089	sessions	_
15-30	3090-3094	were	_
15-31	3095-3110	counterbalanced	_
15-32	3111-3114	for	_
15-33	3115-3120	order	_
15-34	3121-3122	.	_

16-1	3123-3126	All	_
16-2	3127-3139	participants	_
16-3	3140-3148	provided	_
16-4	3149-3157	informed	_
16-5	3158-3165	consent	_
16-6	3166-3169	and	_
16-7	3170-3173	all	_
16-8	3174-3184	procedures	_
16-9	3185-3189	were	_
16-10	3190-3198	approved	_
16-11	3199-3201	by	_
16-12	3202-3205	the	_
16-13	3206-3219	Institutional	_
16-14	3220-3226	Review	_
16-15	3227-3233	Boards	_
16-16	3234-3236	of	_
16-17	3237-3243	Baylor	_
16-18	3244-3251	College	_
16-19	3252-3254	of	_
16-20	3255-3263	Medicine	_
16-21	3264-3267	and	_
16-22	3268-3276	Virginia	_
16-23	3277-3281	Tech	_
16-24	3282-3283	.	_

17-1	3284-3296	Participants	_
17-2	3297-3306	completed	_
17-3	3307-3308	a	_
17-4	3309-3322	probabilistic	_
17-5	3323-3336	loss-learning	http://maven.renci.org/NeuroBridge/neurobridge#II
17-6	3337-3341	task	http://maven.renci.org/NeuroBridge/neurobridge#II
17-7	3342-3343	(	_
17-8	3344-3350	Figure	_
17-9	3351-3353	1A	_
17-10	3354-3355	)	_
17-11	3356-3362	during	_
17-12	3363-3367	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
17-13	3368-3376	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
17-14	3377-3379	in	_
17-15	3380-3383	two	_
17-16	3384-3392	separate	_
17-17	3393-3396	lab	_
17-18	3397-3405	sessions	_
17-19	3406-3407	(	_
17-20	3408-3409	N	_
17-21	3410-3411	=	_
17-22	3412-3414	22	_
17-23	3415-3416	,	_
17-24	3417-3421	each	_
17-25	3422-3429	scanned	_
17-26	3430-3432	in	_
17-27	3433-3437	both	_
17-28	3438-3444	states	_
17-29	3445-3447	of	_
17-30	3448-3455	cocaine	_
17-31	3456-3459	use	_
17-32	3460-3461	;	_
17-33	3462-3465	see	_
17-34	3466-3478	Supplemental	_
17-35	3479-3486	Methods	_
17-36	3487-3490	for	_
17-37	3491-3499	scanning	_
17-38	3500-3510	parameters	_
17-39	3511-3514	and	_
17-40	3515-3528	preprocessing	_
17-41	3529-3539	procedures	_
17-42	3540-3541	)	_
17-43	3542-3543	.	_

18-1	3544-3547	The	_
18-2	3548-3552	task	_
18-3	3553-3561	entailed	_
18-4	3562-3570	learning	_
18-5	3571-3575	from	_
18-6	3576-3584	repeated	_
18-7	3585-3592	choices	_
18-8	3593-3600	between	_
18-9	3601-3604	two	_
18-10	3605-3611	losing	_
18-11	3612-3619	options	_
18-12	3620-3621	(	_
18-13	3622-3629	two-arm	_
18-14	3630-3636	bandit	_
18-15	3637-3639	in	_
18-16	3640-3643	the	_
18-17	3644-3648	loss	_
18-18	3649-3655	domain	_
18-19	3656-3657	;	_
18-20	3658-3661	see	_
18-21	3662-3669	details	_
18-22	3670-3672	in	_
18-23	3673-3685	Supplemental	_
18-24	3686-3693	Methods	_
18-25	3694-3695	;	_
18-26	3696-3703	adapted	_
18-27	3704-3708	from	_
18-28	3709-3710	7	_
18-29	3711-3712	,	_
18-30	3713-3715	20	_
18-31	3716-3717	)	_
18-32	3718-3719	,	_
18-33	3720-3724	with	_
18-34	3725-3728	one	_
18-35	3729-3735	having	_
18-36	3736-3737	a	_
18-37	3738-3744	higher	_
18-38	3745-3756	probability	_
18-39	3757-3759	of	_
18-40	3760-3769	producing	_
18-41	3770-3773	the	_
18-42	3774-3780	better	_
18-43	3781-3788	outcome	_
18-44	3789-3790	(	_
18-45	3791-3795	i.e.	_
18-46	3796-3797	,	_
18-47	3798-3805	smaller	_
18-48	3806-3810	loss	_
18-49	3811-3812	)	_
18-50	3813-3814	.	_

19-1	3815-3817	On	_
19-2	3818-3822	each	_
19-3	3823-3828	trial	_
19-4	3829-3830	,	_
19-5	3831-3839	subjects	_
19-6	3840-3845	chose	_
19-7	3846-3853	between	_
19-8	3854-3857	two	_
19-9	3858-3866	abstract	_
19-10	3867-3874	stimuli	_
19-11	3875-3878	and	_
19-12	3879-3891	subsequently	_
19-13	3892-3900	observed	_
19-14	3901-3904	the	_
19-15	3905-3912	outcome	_
19-16	3913-3914	(	_
19-17	3915-3921	Figure	_
19-18	3922-3924	1A	_
19-19	3925-3926	)	_
19-20	3927-3928	.	_

20-1	3929-3941	Participants	_
20-2	3942-3946	were	_
20-3	3947-3957	instructed	_
20-4	3958-3962	that	_
20-5	3963-3966	one	_
20-6	3967-3973	option	_
20-7	3974-3977	was	_
20-8	3978-3984	better	_
20-9	3985-3989	than	_
20-10	3990-3993	the	_
20-11	3994-3999	other	_
20-12	4000-4003	and	_
20-13	4004-4008	that	_
20-14	4009-4016	payment	_
20-15	4017-4020	was	_
20-16	4021-4028	related	_
20-17	4029-4031	to	_
20-18	4032-4037	their	_
20-19	4038-4045	choices	_
20-20	4046-4049	but	_
20-21	4050-4054	were	_
20-22	4055-4058	not	_
20-23	4059-4069	explicitly	_
20-24	4070-4078	informed	_
20-25	4079-4081	of	_
20-26	4082-4085	the	_
20-27	4086-4093	outcome	_
20-28	4094-4107	probabilities	_
20-29	4108-4110	or	_
20-30	4111-4115	loss	_
20-31	4116-4125	framework	_
20-32	4126-4127	.	_

21-1	4128-4134	Trials	_
21-2	4135-4139	were	_
21-3	4140-4149	presented	_
21-4	4150-4153	for	_
21-5	4154-4155	a	_
21-6	4156-4163	maximum	_
21-7	4164-4166	of	_
21-8	4167-4169	36	_
21-9	4170-4176	trials	_
21-10	4177-4180	per	_
21-11	4181-4186	block	_
21-12	4187-4189	or	_
21-13	4190-4194	when	_
21-14	4195-4205	sufficient	_
21-15	4206-4214	learning	_
21-16	4215-4223	occurred	_
21-17	4224-4225	(	_
21-18	4226-4229	see	_
21-19	4230-4242	Supplemental	_
21-20	4243-4250	Methods	_
21-21	4251-4254	for	_
21-22	4255-4263	learning	_
21-23	4264-4272	criteria	_
21-24	4273-4274	)	_
21-25	4275-4276	.	_

22-1	4277-4281	Each	_
22-2	4282-4287	block	_
22-3	4288-4297	consisted	_
22-4	4298-4300	of	_
22-5	4301-4306	novel	_
22-6	4307-4314	stimuli	_
22-7	4315-4316	,	_
22-8	4317-4322	which	_
22-9	4323-4331	required	_
22-10	4332-4344	participants	_
22-11	4345-4347	to	_
22-12	4348-4353	learn	_
22-13	4354-4357	the	_
22-14	4358-4371	contingencies	_
22-15	4372-4379	between	_
22-16	4380-4387	stimuli	_
22-17	4388-4391	and	_
22-18	4392-4400	outcomes	_
22-19	4401-4407	within	_
22-20	4408-4412	each	_
22-21	4413-4418	block	_
22-22	4419-4420	.	_

23-1	4421-4423	An	_
23-2	4424-4434	additional	_
23-3	4435-4440	group	_
23-4	4441-4443	of	_
23-5	4444-4454	fifty-four	_
23-6	4455-4460	males	_
23-7	4461-4462	(	_
23-8	4463-4466	see	_
23-9	4467-4472	Table	_
23-10	4473-4476	S1A	_
23-11	4477-4480	for	_
23-12	4481-4493	demographics	_
23-13	4494-4495	)	_
23-14	4496-4500	with	_
23-15	4501-4503	no	_
23-16	4504-4511	history	_
23-17	4512-4514	of	_
23-18	4515-4521	Axis-I	_
23-19	4522-4537	psychopathology	_
23-20	4538-4542	were	_
23-21	4543-4547	used	_
23-22	4548-4550	as	_
23-23	4551-4553	an	_
23-24	4554-4565	independent	_
23-25	4566-4581	non-psychiatric	_
23-26	4582-4589	control	_
23-27	4590-4596	sample	_
23-28	4597-4599	to	_
23-29	4600-4608	identity	_
23-30	4609-4625	learning-related	_
23-31	4626-4634	striatum	_
23-32	4635-4645	activation	_
23-33	4646-4650	that	_
23-34	4651-4656	could	_
23-35	4657-4659	be	_
23-36	4660-4664	used	_
23-37	4665-4667	as	_
23-38	4668-4669	a	_
23-39	4670-4679	reference	_
23-40	4680-4687	against	_
23-41	4688-4693	which	_
23-42	4694-4696	to	_
23-43	4697-4706	interpret	_
23-44	4707-4710	any	_
23-45	4711-4717	neural	_
23-46	4718-4725	effects	_
23-47	4726-4734	observed	_
23-48	4735-4737	in	_
23-49	4738-4741	the	_
23-50	4742-4745	CUD	_
23-51	4746-4757	individuals	_
23-52	4758-4759	,	_
23-53	4760-4763	and	_
23-54	4764-4766	to	_
23-55	4767-4774	compute	_
23-56	4775-4790	non-psychiatric	_
23-57	4791-4801	individual	_
23-58	4802-4811	parameter	_
23-59	4812-4821	estimates	_
23-60	4822-4825	for	_
23-61	4826-4831	model	_
23-62	4832-4842	validation	_
23-63	4843-4846	and	_
23-64	4847-4856	parameter	_
23-65	4857-4865	recovery	_
23-66	4866-4867	.	_

24-1	4868-4878	Behavioral	_
24-2	4879-4887	Analyses	_
24-3	4888-4902	Model-agnostic	_
24-4	4903-4913	behavioral	_
24-5	4914-4922	analyses	_
24-6	4923-4924	.	_

25-1	4925-4927	To	_
25-2	4928-4934	verify	_
25-3	4935-4939	that	_
25-4	4940-4952	participants	_
25-5	4953-4960	learned	_
25-6	4961-4967	during	_
25-7	4968-4971	the	_
25-8	4972-4976	task	_
25-9	4977-4978	,	_
25-10	4979-4982	the	_
25-11	4983-4993	behavioral	_
25-12	4994-5001	choices	_
25-13	5002-5004	of	_
25-14	5005-5009	each	_
25-15	5010-5020	individual	_
25-16	5021-5023	in	_
25-17	5024-5028	each	_
25-18	5029-5037	drug-use	_
25-19	5038-5043	state	_
25-20	5044-5048	were	_
25-21	5049-5057	examined	_
25-22	5058-5062	over	_
25-23	5063-5067	time	_
25-24	5068-5071	and	_
25-25	5072-5082	quantified	_
25-26	5083-5085	as	_
25-27	5086-5089	the	_
25-28	5090-5100	percentage	_
25-29	5101-5103	of	_
25-30	5104-5110	trials	_
25-31	5111-5115	that	_
25-32	5116-5119	the	_
25-33	5120-5131	objectively	_
25-34	5132-5138	better	_
25-35	5139-5145	choice	_
25-36	5146-5149	was	_
25-37	5150-5158	selected	_
25-38	5159-5160	.	_

26-1	5161-5168	Within-	_
26-2	5169-5175	sample	_
26-3	5176-5179	and	_
26-4	5180-5186	paired	_
26-5	5187-5194	t-tests	_
26-6	5195-5197	on	_
26-7	5198-5209	performance	_
26-8	5210-5214	were	_
26-9	5215-5226	implemented	_
26-10	5227-5229	in	_
26-11	5230-5236	MATLAB	_
26-12	5237-5238	.	_

27-1	5239-5252	Computational	_
27-2	5253-5264	model-based	_
27-3	5265-5275	behavioral	_
27-4	5276-5284	analyses	_
27-5	5285-5286	.	_

28-1	5287-5289	To	_
28-2	5290-5296	assess	_
28-3	5297-5310	model-derived	_
28-4	5311-5321	behavioral	_
28-5	5322-5330	learning	_
28-6	5331-5338	effects	_
28-7	5339-5342	for	_
28-8	5343-5347	each	_
28-9	5348-5359	participant	_
28-10	5360-5362	in	_
28-11	5363-5367	each	_
28-12	5368-5376	drug-use	_
28-13	5377-5382	state	_
28-14	5383-5384	,	_
28-15	5385-5397	participants	_
28-16	5398-5399	’	_
28-17	5400-5410	behavioral	_
28-18	5411-5418	choices	_
28-19	5419-5423	were	_
28-20	5424-5427	fit	_
28-21	5428-5430	to	_
28-22	5431-5432	a	_
28-23	5433-5438	basic	_
28-24	5439-5452	reinforcement	_
28-25	5453-5463	Q-learning	_
28-26	5464-5469	model	_
28-27	5470-5475	which	_
28-28	5476-5484	included	_
28-29	5485-5488	two	_
28-30	5489-5497	learning	_
28-31	5498-5503	rates	_
28-32	5504-5505	(	_
28-33	5506-5507	α	_
28-34	5508-5509	)	_
28-35	5510-5514	that	_
28-36	5515-5523	provided	_
28-37	5524-5532	separate	_
28-38	5533-5539	update	_
28-39	5540-5545	rules	_
28-40	5546-5549	for	_
28-41	5550-5558	positive	_
28-42	5559-5560	(	_
28-43	5561-5563	δ+	_
28-44	5564-5565	)	_
28-45	5566-5569	and	_
28-46	5570-5578	negative	_
28-47	5579-5580	(	_
28-48	5581-5583	δ-	_
28-49	5584-5585	)	_
28-50	5586-5596	prediction	_
28-51	5597-5603	errors	_
28-52	5604-5605	(	_
28-53	5606-5612	better	_
28-54	5613-5615	or	_
28-55	5616-5621	worse	_
28-56	5622-5626	than	_
28-57	5627-5639	expectations	_
28-58	5640-5641	,	_
28-59	5642-5649	mapping	_
28-60	5650-5652	on	_
28-61	5653-5655	to	_
28-62	5656-5666	successful	_
28-63	5667-5670	and	_
28-64	5671-5683	unsuccessful	_
28-65	5684-5688	loss	_
28-66	5689-5698	avoidance	_
28-67	5699-5700	;	_
28-68	5701-5703	d+	_
28-69	5704-5707	and	_
28-70	5708-5710	S-	_
28-71	5711-5712	,	_
28-72	5713-5720	adapted	_
28-73	5721-5725	from	_
28-74	5726-5734	previous	_
28-75	5735-5742	studies	_
28-76	5743-5744	,	_
28-77	5745-5747	in	_
28-78	5748-5751	the	_
28-79	5752-5756	form	_
28-80	5757-5759	of	_
28-81	5760-5768	positive	_
28-82	5769-5770	(	_
28-83	5771-5773	α+	_
28-84	5774-5775	)	_
28-85	5776-5779	and	_
28-86	5780-5788	negative	_
28-87	5789-5790	(	_
28-88	5791-5793	α-	_
28-89	5794-5795	)	_
28-90	5796-5804	learning	_
28-91	5805-5810	rates	_
28-92	5811-5812	(	_
28-93	5813-5819	Figure	_
28-94	5820-5822	1B	_
28-95	5823-5824	)	_
28-96	5825-5826	.	_

29-1	5827-5830	The	_
29-2	5831-5839	separate	_
29-3	5840-5848	learning	_
29-4	5849-5854	rates	_
29-5	5855-5862	allowed	_
29-6	5863-5865	us	_
29-7	5866-5868	to	_
29-8	5869-5877	evaluate	_
29-9	5878-5889	asymmetries	_
29-10	5890-5892	in	_
29-11	5893-5901	learning	_
29-12	5902-5906	from	_
29-13	5907-5909	δ+	_
29-14	5910-5913	and	_
29-15	5914-5916	δ-	_
29-16	5917-5918	(	_
29-17	5919-5923	e.g.	_
29-18	5924-5925	,	_
29-19	5926-5927	)	_
29-20	5928-5931	and	_
29-21	5932-5938	assess	_
29-22	5939-5942	the	_
29-23	5943-5954	possibility	_
29-24	5955-5959	that	_
29-25	5960-5967	cocaine	_
29-26	5968-5969	’	_
29-27	5970-5971	s	_
29-28	5972-5979	effects	_
29-29	5980-5982	on	_
29-30	5983-5985	DA	_
29-31	5986-5993	systems	_
29-32	5994-6008	differentially	_
29-33	6009-6015	impact	_
29-34	6016-6021	these	_
29-35	6022-6032	components	_
29-36	6033-6034	.	_

30-1	6035-6038	The	_
30-2	6039-6044	model	_
30-3	6045-6048	was	_
30-4	6049-6050	a	_
30-5	6051-6055	good	_
30-6	6056-6059	fit	_
30-7	6060-6062	of	_
30-8	6063-6075	participants	_
30-9	6076-6077	’	_
30-10	6078-6085	choices	_
30-11	6086-6092	during	_
30-12	6093-6096	the	_
30-13	6097-6102	loss-	_
30-14	6103-6111	learning	_
30-15	6112-6116	task	_
30-16	6117-6118	(	_
30-17	6119-6125	Figure	_
30-18	6126-6128	1C	_
30-19	6129-6130	)	_
30-20	6131-6132	,	_
30-21	6133-6136	was	_
30-22	6137-6138	a	_
30-23	6139-6145	better	_
30-24	6146-6149	fit	_
30-25	6150-6154	then	_
30-26	6155-6156	a	_
30-27	6157-6163	single	_
30-28	6164-6172	learning	_
30-29	6173-6177	rate	_
30-30	6178-6183	model	_
30-31	6184-6185	,	_
30-32	6186-6189	and	_
30-33	6190-6195	model	_
30-34	6196-6199	and	_
30-35	6200-6209	parameter	_
30-36	6210-6218	recovery	_
30-37	6219-6224	using	_
30-38	6225-6234	simulated	_
30-39	6235-6239	data	_
30-40	6240-6247	further	_
30-41	6248-6256	verified	_
30-42	6257-6260	the	_
30-43	6261-6264	fit	_
30-44	6265-6267	of	_
30-45	6268-6271	the	_
30-46	6272-6277	model	_
30-47	6278-6280	to	_
30-48	6281-6284	the	_
30-49	6285-6293	observed	_
30-50	6294-6302	behavior	_
30-51	6303-6304	(	_
30-52	6305-6308	see	_
30-53	6309-6319	Behavioral	_
30-54	6320-6327	Results	_
30-55	6328-6329	)	_
30-56	6330-6331	.	_

31-1	6332-6333	A	_
31-2	6334-6339	third	_
31-3	6340-6349	estimated	_
31-4	6350-6359	parameter	_
31-5	6360-6361	,	_
31-6	6362-6369	inverse	_
31-7	6370-6381	temperature	_
31-8	6382-6383	(	_
31-9	6384-6385	β	_
31-10	6386-6387	)	_
31-11	6388-6389	,	_
31-12	6390-6398	provided	_
31-13	6399-6400	a	_
31-14	6401-6408	measure	_
31-15	6409-6411	of	_
31-16	6412-6423	exploration	_
31-17	6424-6427	and	_
31-18	6428-6437	indicated	_
31-19	6438-6441	the	_
31-20	6442-6453	sensitivity	_
31-21	6454-6456	of	_
31-22	6457-6463	choice	_
31-23	6464-6477	probabilities	_
31-24	6478-6480	to	_
31-25	6481-6492	differences	_
31-26	6493-6495	in	_
31-27	6496-6502	values	_
31-28	6503-6504	.	_

32-1	6505-6508	See	_
32-2	6509-6521	Supplemental	_
32-3	6522-6529	Methods	_
32-4	6530-6533	for	_
32-5	6534-6544	additional	_
32-6	6545-6557	descriptions	_
32-7	6558-6560	of	_
32-8	6561-6566	model	_
32-9	6567-6576	selection	_
32-10	6577-6578	,	_
32-11	6579-6584	model	_
32-12	6585-6595	validation	_
32-13	6596-6597	,	_
32-14	6598-6601	and	_
32-15	6602-6611	parameter	_
32-16	6612-6620	recovery	_
32-17	6621-6631	procedures	_
32-18	6632-6633	(	_
32-19	6634-6646	Supplemental	_
32-20	6647-6654	Methods	_
32-21	6655-6656	,	_
32-22	6657-6662	Model	_
32-23	6663-6670	Fitting	_
32-24	6671-6674	and	_
32-25	6675-6684	Selection	_
32-26	6685-6686	)	_
32-27	6687-6688	.	_

33-1	6689-6692	For	_
33-2	6693-6696	the	_
33-3	6697-6700	two	_
33-4	6701-6709	learning	_
33-5	6710-6714	rate	_
33-6	6715-6720	model	_
33-7	6721-6722	,	_
33-8	6723-6726	the	_
33-9	6727-6734	initial	_
33-10	6735-6743	expected	_
33-11	6744-6750	values	_
33-12	6751-6752	Q	_
33-13	6753-6754	(	_
33-14	6755-6756	0	_
33-15	6757-6758	)	_
33-16	6759-6762	for	_
33-17	6763-6766	the	_
33-18	6767-6775	possible	_
33-19	6776-6783	choices	_
33-20	6784-6785	a	_
33-21	6786-6789	and	_
33-22	6790-6791	b	_
33-23	6792-6796	were	_
33-24	6797-6800	set	_
33-25	6801-6803	to	_
33-26	6804-6805	0	_
33-27	6806-6808	as	_
33-28	6809-6821	participants	_
33-29	6822-6826	were	_
33-30	6827-6830	not	_
33-31	6831-6841	instructed	_
33-32	6842-6843	a	_
33-33	6844-6850	priori	_
33-34	6851-6856	about	_
33-35	6857-6860	the	_
33-36	6861-6866	range	_
33-37	6867-6869	of	_
33-38	6870-6878	possible	_
33-39	6879-6887	outcomes	_
33-40	6888-6889	.	_

34-1	6890-6893	For	_
34-2	6894-6899	trial	_
34-3	6900-6906	number	_
34-4	6907-6908	t	_
34-5	6909-6910	,	_
34-6	6911-6914	the	_
34-7	6915-6922	outcome	_
34-8	6923-6926	for	_
34-9	6927-6930	the	_
34-10	6931-6937	chosen	_
34-11	6938-6944	option	_
34-12	6945-6946	a	_
34-13	6947-6950	was	_
34-14	6951-6962	represented	_
34-15	6963-6965	by	_
34-16	6966-6968	Ra	_
34-17	6969-6970	(	_
34-18	6971-6972	t	_
34-19	6973-6974	)	_
34-20	6975-6979	with	_
34-21	6980-6983	the	_
34-22	6984-6992	expected	_
34-23	6993-6998	value	_
34-24	6999-7010	represented	_
34-25	7011-7013	by	_
34-26	7014-7016	Qa	_
34-27	7017-7018	(	_
34-28	7019-7020	t	_
34-29	7021-7022	)	_
34-30	7023-7024	.	_

35-1	7025-7028	The	_
35-2	7029-7039	prediction	_
35-3	7040-7045	error	_
35-4	7046-7047	δ	_
35-5	7048-7049	(	_
35-6	7050-7051	t	_
35-7	7052-7053	)	_
35-8	7054-7055	,	_
35-9	7056-7061	which	_
35-10	7062-7070	measures	_
35-11	7071-7074	the	_
35-12	7075-7085	difference	_
35-13	7086-7088	in	_
35-14	7089-7096	outcome	_
35-15	7097-7099	Ra	_
35-16	7100-7101	(	_
35-17	7102-7103	t	_
35-18	7104-7105	)	_
35-19	7106-7109	and	_
35-20	7110-7121	expectation	_
35-21	7122-7124	Qa	_
35-22	7125-7126	(	_
35-23	7127-7128	t	_
35-24	7129-7130	)	_
35-25	7131-7132	,	_
35-26	7133-7136	for	_
35-27	7137-7138	a	_
35-28	7139-7144	trial	_
35-29	7145-7148	was	_
35-30	7149-7156	defined	_
35-31	7157-7159	as	_
35-32	7160-7167	follows	_
35-33	7168-7169	:	_
35-34	7170-7173	The	_
35-35	7174-7183	parameter	_
35-36	7184-7194	estimation	_
35-37	7195-7205	procedures	_
35-38	7206-7214	included	_
35-39	7215-7223	separate	_
35-40	7224-7230	update	_
35-41	7231-7236	rules	_
35-42	7237-7240	for	_
35-43	7241-7249	positive	_
35-44	7250-7253	and	_
35-45	7254-7262	negative	_
35-46	7263-7273	prediction	_
35-47	7274-7280	errors	_
35-48	7281-7282	δ	_
35-49	7283-7284	(	_
35-50	7285-7286	t	_
35-51	7287-7288	)	_
35-52	7289-7291	in	_
35-53	7292-7295	the	_
35-54	7296-7300	form	_
35-55	7301-7303	of	_
35-56	7304-7312	positive	_
35-57	7313-7314	(	_
35-58	7315-7317	α+	_
35-59	7318-7319	)	_
35-60	7320-7323	and	_
35-61	7324-7332	negative	_
35-62	7333-7334	(	_
35-63	7335-7337	α-	_
35-64	7338-7339	)	_
35-65	7340-7348	learning	_
35-66	7349-7354	rates	_
35-67	7355-7356	,	_
35-68	7357-7369	respectively	_
35-69	7370-7371	(	_
35-70	7372-7378	Figure	_
35-71	7379-7381	1B	_
35-72	7382-7383	)	_
35-73	7384-7385	.	_

36-1	7386-7389	The	_
36-2	7390-7398	learning	_
36-3	7399-7403	rate	_
36-4	7404-7414	parameters	_
36-5	7415-7423	quantify	_
36-6	7424-7427	how	_
36-7	7428-7432	much	_
36-8	7433-7439	weight	_
36-9	7440-7443	the	_
36-10	7444-7454	prediction	_
36-11	7455-7460	error	_
36-12	7461-7462	δ	_
36-13	7463-7464	(	_
36-14	7465-7466	t	_
36-15	7467-7468	)	_
36-16	7469-7473	from	_
36-17	7474-7481	current	_
36-18	7482-7488	trials	_
36-19	7489-7491	is	_
36-20	7492-7497	given	_
36-21	7498-7500	in	_
36-22	7501-7509	updating	_
36-23	7510-7513	the	_
36-24	7514-7523	following	_
36-25	7524-7530	trials	_
36-26	7531-7532	’	_
36-27	7533-7541	expected	_
36-28	7542-7547	value	_
36-29	7548-7550	Qa	_
36-30	7551-7552	(	_
36-31	7553-7556	t+1	_
36-32	7557-7558	)	_
36-33	7559-7560	:	_
36-34	7561-7562	A	_
36-35	7563-7571	standard	_
36-36	7572-7579	softmax	_
36-37	7580-7586	action	_
36-38	7587-7596	selection	_
36-39	7597-7605	function	_
36-40	7606-7609	was	_
36-41	7610-7614	used	_
36-42	7615-7617	to	_
36-43	7618-7627	calculate	_
36-44	7628-7631	the	_
36-45	7632-7643	probability	_
36-46	7644-7646	of	_
36-47	7647-7656	selecting	_
36-48	7657-7663	choice	_
36-49	7664-7665	a	_
36-50	7666-7668	at	_
36-51	7669-7673	time	_
36-52	7674-7675	t	_
36-53	7676-7679	and	_
36-54	7680-7683	was	_
36-55	7684-7695	implemented	_
36-56	7696-7698	as	_
36-57	7699-7706	follows	_
36-58	7707-7708	:	_
36-59	7709-7717	Positive	_
36-60	7718-7721	and	_
36-61	7722-7730	negative	_
36-62	7731-7739	learning	_
36-63	7740-7745	rates	_
36-64	7746-7747	(	_
36-65	7748-7750	α+	_
36-66	7751-7754	and	_
36-67	7755-7757	α-	_
36-68	7758-7759	)	_
36-69	7760-7763	and	_
36-70	7764-7771	inverse	_
36-71	7772-7783	temperature	_
36-72	7784-7785	β	_
36-73	7786-7790	were	_
36-74	7791-7795	free	_
36-75	7796-7806	parameters	_
36-76	7807-7808	,	_
36-77	7809-7820	iteratively	_
36-78	7821-7830	estimated	_
36-79	7831-7833	in	_
36-80	7834-7840	MATLAB	_
36-81	7841-7846	using	_
36-82	7847-7850	the	_
36-83	7851-7859	function	_
36-84	7860-7870	fminsearch	_
36-85	7871-7872	,	_
36-86	7873-7877	that	_
36-87	7878-7882	were	_
36-88	7883-7892	evaluated	_
36-89	7893-7895	to	_
36-90	7896-7900	have	_
36-91	7901-7904	the	_
36-92	7905-7912	maximum	_
36-93	7913-7916	log	_
36-94	7917-7927	likelihood	_
36-95	7928-7929	.	_

37-1	7930-7938	Learning	_
37-2	7939-7944	rates	_
37-3	7945-7949	were	_
37-4	7950-7957	bounded	_
37-5	7958-7965	between	_
37-6	7966-7969	0:1	_
37-7	7970-7973	and	_
37-8	7974-7981	inverse	_
37-9	7982-7993	temperature	_
37-10	7994-7997	was	_
37-11	7998-8005	bounded	_
37-12	8006-8013	between	_
37-13	8014-8015	0	_
37-14	8016-8017	:	_
37-15	8018-8019	∞	_
37-16	8020-8021	.	_

38-1	8022-8025	For	_
38-2	8026-8029	the	_
38-3	8030-8038	unchosen	_
38-4	8039-8045	option	_
38-5	8046-8047	b	_
38-6	8048-8049	,	_
38-7	8050-8053	the	_
38-8	8054-8062	expected	_
38-9	8063-8068	value	_
38-10	8069-8071	of	_
38-11	8072-8075	the	_
38-12	8076-8086	subsequent	_
38-13	8087-8092	trial	_
38-14	8093-8096	was	_
38-15	8097-8100	set	_
38-16	8101-8103	to	_
38-17	8104-8107	the	_
38-18	8108-8115	current	_
38-19	8116-8121	trial	_
38-20	8122-8123	’	_
38-21	8124-8125	s	_
38-22	8126-8134	expected	_
38-23	8135-8140	value	_
38-24	8141-8143	Qb	_
38-25	8144-8145	(	_
38-26	8146-8147	t	_
38-27	8148-8149	)	_
38-28	8150-8160	multiplied	_
38-29	8161-8163	by	_
38-30	8164-8166	an	_
38-31	8167-8177	additional	_
38-32	8178-8183	decay	_
38-33	8184-8193	parameter	_
38-34	8194-8195	(	_
38-35	8196-8197	ϕ	_
38-36	8198-8199	,	_
38-37	8200-8207	bounded	_
38-38	8208-8215	between	_
38-39	8216-8217	0	_
38-40	8218-8219	:	_
38-41	8220-8221	∞	_
38-42	8222-8223	)	_
38-43	8224-8231	similar	_
38-44	8232-8234	to	_
38-45	8235-8243	previous	_
38-46	8244-8251	studies	_
38-47	8252-8253	.	_

39-1	8254-8264	Individual	_
39-2	8265-8274	variances	_
39-3	8275-8277	in	_
39-4	8278-8286	learning	_
39-5	8287-8292	rates	_
39-6	8293-8294	(	_
39-7	8295-8297	α-	_
39-8	8298-8301	and	_
39-9	8302-8304	α+	_
39-10	8305-8306	)	_
39-11	8307-8309	as	_
39-12	8310-8312	an	_
39-13	8313-8319	effect	_
39-14	8320-8322	of	_
39-15	8323-8333	drug-state	_
39-16	8334-8335	(	_
39-17	8336-8338	C-	_
39-18	8339-8341	or	_
39-19	8342-8344	C+	_
39-20	8345-8346	)	_
39-21	8347-8351	were	_
39-22	8352-8361	estimated	_
39-23	8362-8365	for	_
39-24	8366-8372	second	_
39-25	8373-8378	level	_
39-26	8379-8383	fMRI	_
39-27	8384-8392	analysis	_
39-28	8393-8394	(	_
39-29	8395-8398	see	_
39-30	8399-8406	Imaging	_
39-31	8407-8415	Analysis	_
39-32	8416-8421	below	_
39-33	8422-8423	)	_
39-34	8424-8425	.	_

40-1	8426-8431	First	_
40-2	8432-8433	,	_
40-3	8434-8437	the	_
40-4	8438-8443	prior	_
40-5	8444-8448	mean	_
40-6	8449-8452	and	_
40-7	8453-8465	distribution	_
40-8	8466-8468	of	_
40-9	8469-8477	learning	_
40-10	8478-8483	rates	_
40-11	8484-8487	for	_
40-12	8488-8500	participants	_
40-13	8501-8503	in	_
40-14	8504-8508	each	_
40-15	8509-8513	drug	_
40-16	8514-8519	state	_
40-17	8520-8521	(	_
40-18	8522-8524	C-	_
40-19	8525-8528	and	_
40-20	8529-8531	C+	_
40-21	8532-8533	)	_
40-22	8534-8538	were	_
40-23	8539-8548	estimated	_
40-24	8549-8554	using	_
40-25	8555-8567	bootstrapped	_
40-26	8568-8575	maximum	_
40-27	8576-8586	likelihood	_
40-28	8587-8594	created	_
40-29	8595-8598	via	_
40-30	8599-8607	sampling	_
40-31	8608-8609	,	_
40-32	8610-8623	approximating	_
40-33	8624-8635	integration	_
40-34	8636-8637	,	_
40-35	8638-8644	around	_
40-36	8645-8646	a	_
40-37	8647-8659	bootstrapped	_
40-38	8660-8667	maximum	_
40-39	8668-8678	likelihood	_
40-40	8679-8689	estimation	_
40-41	8690-8696	across	_
40-42	8697-8705	subjects	_
40-43	8706-8707	.	_

41-1	8708-8718	Individual	_
41-2	8719-8727	learning	_
41-3	8728-8733	rates	_
41-4	8734-8738	were	_
41-5	8739-8751	subsequently	_
41-6	8752-8761	estimated	_
41-7	8762-8764	by	_
41-8	8765-8777	conditioning	_
41-9	8778-8789	individuals	_
41-10	8790-8791	’	_
41-11	8792-8802	behavioral	_
41-12	8803-8807	data	_
41-13	8808-8810	on	_
41-14	8811-8814	the	_
41-15	8815-8825	respective	_
41-16	8826-8830	drug	_
41-17	8831-8836	state	_
41-18	8837-8838	(	_
41-19	8839-8841	C-	_
41-20	8842-8844	or	_
41-21	8845-8847	C+	_
41-22	8848-8849	)	_
41-23	8850-8855	group	_
41-24	8856-8857	’	_
41-25	8858-8859	s	_
41-26	8860-8865	prior	_
41-27	8866-8878	distribution	_
41-28	8879-8881	to	_
41-29	8882-8889	account	_
41-30	8890-8893	for	_
41-31	8894-8902	drug-use	_
41-32	8903-8909	status	_
41-33	8910-8921	differences	_
41-34	8922-8923	.	_

42-1	8924-8927	For	_
42-2	8928-8932	each	_
42-3	8933-8944	participant	_
42-4	8945-8946	,	_
42-5	8947-8957	individual	_
42-6	8958-8960	C+	_
42-7	8961-8969	learning	_
42-8	8970-8975	rates	_
42-9	8976-8980	were	_
42-10	8981-8985	then	_
42-11	8986-8996	subtracted	_
42-12	8997-9001	from	_
42-13	9002-9005	the	_
42-14	9006-9016	individual	_
42-15	9017-9019	C-	_
42-16	9020-9028	learning	_
42-17	9029-9034	rates	_
42-18	9035-9037	to	_
42-19	9038-9045	compute	_
42-20	9046-9047	a	_
42-21	9048-9055	cocaine	_
42-22	9056-9057	‘	_
42-23	9058-9069	deprivation	_
42-24	9070-9078	enhanced	_
42-25	9079-9080	’	_
42-26	9081-9089	learning	_
42-27	9090-9094	rate	_
42-28	9095-9098	for	_
42-29	9099-9103	each	_
42-30	9104-9115	participant	_
42-31	9116-9117	.	_

43-1	9118-9123	Group	_
43-2	9124-9132	specific	_
43-3	9133-9145	bootstrapped	_
43-4	9146-9155	estimates	_
43-5	9156-9160	were	_
43-6	9161-9165	used	_
43-7	9166-9169	for	_
43-8	9170-9173	the	_
43-9	9174-9181	inverse	_
43-10	9182-9193	temperature	_
43-11	9194-9197	and	_
43-12	9198-9203	decay	_
43-13	9204-9214	parameters	_
43-14	9215-9221	during	_
43-15	9222-9232	individual	_
43-16	9233-9243	estimation	_
43-17	9244-9246	of	_
43-18	9247-9255	learning	_
43-19	9256-9261	rates	_
43-20	9262-9263	.	_

44-1	9264-9271	Imaging	_
44-2	9272-9280	Analyses	_
44-3	9281-9283	To	_
44-4	9284-9291	examine	_
44-5	9292-9298	neural	_
44-6	9299-9309	substrates	_
44-7	9310-9312	of	_
44-8	9313-9317	loss	_
44-9	9318-9326	learning	_
44-10	9327-9337	associated	_
44-11	9338-9342	with	_
44-12	9343-9350	cocaine	_
44-13	9351-9360	use-state	_
44-14	9361-9363	in	_
44-15	9364-9373	dependent	_
44-16	9374-9385	individuals	_
44-17	9386-9387	,	_
44-18	9388-9401	model-derived	_
44-19	9402-9410	learning	_
44-20	9411-9420	variables	_
44-21	9421-9424	fit	_
44-22	9425-9431	across	_
44-23	9432-9435	all	_
44-24	9436-9448	participants	_
44-25	9449-9450	(	_
44-26	9451-9453	as	_
44-27	9454-9463	described	_
44-28	9464-9469	above	_
44-29	9470-9471	)	_
44-30	9472-9476	were	_
44-31	9477-9482	first	_
44-32	9483-9493	correlated	_
44-33	9494-9498	with	_
44-34	9499-9509	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
44-35	9510-9513	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
44-36	9514-9518	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
44-37	9519-9528	collected	_
44-38	9529-9535	during	_
44-39	9536-9539	the	_
44-40	9540-9553	loss-learning	_
44-41	9554-9558	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
44-42	9559-9560	.	_

45-1	9561-9565	Next	_
45-2	9566-9567	,	_
45-3	9568-9571	the	_
45-4	9572-9583	model-based	_
45-5	9584-9590	neural	_
45-6	9591-9601	prediction	_
45-7	9602-9607	error	_
45-8	9608-9615	signals	_
45-9	9616-9620	were	_
45-10	9621-9628	related	_
45-11	9629-9631	to	_
45-12	9632-9644	participants	_
45-13	9645-9646	’	_
45-14	9647-9660	self-reported	_
45-15	9661-9668	cocaine	_
45-16	9669-9672	use	_
45-17	9673-9681	measures	_
45-18	9682-9683	.	_

46-1	9684-9695	First-level	_
46-2	9696-9700	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
46-3	9701-9711	processing	_
46-4	9712-9713	.	_

47-1	9714-9717	The	_
47-2	9718-9725	general	_
47-3	9726-9732	linear	_
47-4	9733-9738	model	_
47-5	9739-9740	(	_
47-6	9741-9744	GLM	_
47-7	9745-9746	)	_
47-8	9747-9758	implemented	_
47-9	9759-9761	in	_
47-10	9762-9766	SPM8	_
47-11	9767-9770	was	_
47-12	9771-9775	used	_
47-13	9776-9778	to	_
47-14	9779-9786	perform	_
47-15	9787-9799	neuroimaging	_
47-16	9800-9808	analyses	_
47-17	9809-9811	at	_
47-18	9812-9815	the	_
47-19	9816-9826	individual	_
47-20	9827-9830	and	_
47-21	9831-9836	group	_
47-22	9837-9843	levels	_
47-23	9844-9845	.	_

48-1	9846-9849	For	_
48-2	9850-9853	the	_
48-3	9854-9859	first	_
48-4	9860-9865	level	_
48-5	9866-9874	analyses	_
48-6	9875-9876	,	_
48-7	9877-9882	onset	_
48-8	9883-9888	times	_
48-9	9889-9892	for	_
48-10	9893-9900	stimuli	_
48-11	9901-9902	,	_
48-12	9903-9910	outcome	_
48-13	9911-9917	events	_
48-14	9918-9921	for	_
48-15	9922-9924	δ+	_
48-16	9925-9933	outcomes	_
48-17	9934-9935	,	_
48-18	9936-9939	and	_
48-19	9940-9947	outcome	_
48-20	9948-9954	events	_
48-21	9955-9958	for	_
48-22	9959-9961	δ-	_
48-23	9962-9970	outcomes	_
48-24	9971-9974	for	_
48-25	9975-9979	each	_
48-26	9980-9985	trial	_
48-27	9986-9990	were	_
48-28	9991-9998	modeled	_
48-29	9999-10001	as	_
48-30	10002-10010	separate	_
48-31	10011-10019	punctate	_
48-32	10020-10026	events	_
48-33	10027-10028	.	_

49-1	10029-10032	The	_
49-2	10033-10041	outcomes	_
49-3	10042-10046	were	_
49-4	10047-10058	categorized	_
49-5	10059-10064	based	_
49-6	10065-10067	on	_
49-7	10068-10071	the	_
49-8	10072-10076	sign	_
49-9	10077-10079	of	_
49-10	10080-10083	the	_
49-11	10084-10094	prediction	_
49-12	10095-10100	error	_
49-13	10101-10102	(	_
49-14	10103-10104	δ	_
49-15	10105-10106	>	_
49-16	10107-10108	0	_
49-17	10109-10111	or	_
49-18	10112-10113	δ	_
49-19	10114-10115	<	_
49-20	10116-10117	0	_
49-21	10118-10119	,	_
49-22	10120-10130	indicating	_
49-23	10131-10133	δ+	_
49-24	10134-10137	and	_
49-25	10138-10140	δ-	_
49-26	10141-10142	)	_
49-27	10143-10144	,	_
49-28	10145-10150	using	_
49-29	10151-10154	the	_
49-30	10155-10161	fitted	_
49-31	10162-10171	estimates	_
49-32	10172-10174	of	_
49-33	10175-10178	the	_
49-34	10179-10180	2	_
49-35	10181-10189	Learning	_
49-36	10190-10194	Rate	_
49-37	10195-10200	model	_
49-38	10201-10202	,	_
49-39	10203-10205	in	_
49-40	10206-10211	which	_
49-41	10212-10226	trial-by-trial	_
49-42	10227-10229	δs	_
49-43	10230-10234	were	_
49-44	10235-10244	generated	_
49-45	10245-10246	(	_
49-46	10247-10250	see	_
49-47	10251-10260	procedure	_
49-48	10261-10263	in	_
49-49	10264-10276	Supplemental	_
49-50	10277-10284	Methods	_
49-51	10285-10286	)	_
49-52	10287-10288	.	_

50-1	10289-10291	To	_
50-2	10292-10299	examine	_
50-3	10300-10303	the	_
50-4	10304-10309	first	_
50-5	10310-10315	level	_
50-6	10316-10323	effects	_
50-7	10324-10326	of	_
50-8	10327-10335	drug-use	_
50-9	10336-10342	status	_
50-10	10343-10345	on	_
50-11	10346-10352	neural	_
50-12	10353-10367	representation	_
50-13	10368-10370	of	_
50-14	10371-10379	learning	_
50-15	10380-10383	and	_
50-16	10384-10393	valuation	_
50-17	10394-10395	,	_
50-18	10396-10403	cocaine	_
50-19	10404-10412	positive	_
50-20	10413-10414	(	_
50-21	10415-10417	C+	_
50-22	10418-10419	,	_
50-23	10420-10425	urine	_
50-24	10426-10434	positive	_
50-25	10435-10438	for	_
50-26	10439-10446	cocaine	_
50-27	10447-10458	metabolites	_
50-28	10459-10460	)	_
50-29	10461-10464	and	_
50-30	10465-10472	cocaine	_
50-31	10473-10481	negative	_
50-32	10482-10483	(	_
50-33	10484-10486	C-	_
50-34	10487-10488	,	_
50-35	10489-10494	urine	_
50-36	10495-10503	negative	_
50-37	10504-10507	for	_
50-38	10508-10515	cocaine	_
50-39	10516-10527	metabolites	_
50-40	10528-10529	)	_
50-41	10530-10534	drug	_
50-42	10535-10538	use	_
50-43	10539-10545	states	_
50-44	10546-10549	for	_
50-45	10550-10554	each	_
50-46	10555-10565	individual	_
50-47	10566-10570	were	_
50-48	10571-10578	modeled	_
50-49	10579-10581	as	_
50-50	10582-10590	separate	_
50-51	10591-10596	first	_
50-52	10597-10602	level	_
50-53	10603-10607	GLMs	_
50-54	10608-10609	.	_

51-1	10610-10624	Trial-by-trial	_
51-2	10625-10633	expected	_
51-3	10634-10640	values	_
51-4	10641-10642	(	_
51-5	10643-10644	Q	_
51-6	10645-10646	)	_
51-7	10647-10651	were	_
51-8	10652-10659	modeled	_
51-9	10660-10662	as	_
51-10	10663-10673	parametric	_
51-11	10674-10684	regressors	_
51-12	10685-10689	onto	_
51-13	10690-10693	the	_
51-14	10694-10702	response	_
51-15	10703-10709	events	_
51-16	10710-10711	.	_

52-1	10712-10726	Trial-by-trial	_
52-2	10727-10729	δ+	_
52-3	10730-10733	and	_
52-4	10734-10736	δ-	_
52-5	10737-10738	,	_
52-6	10739-10742	and	_
52-7	10743-10746	the	_
52-8	10747-10753	actual	_
52-9	10754-10762	outcomes	_
52-10	10763-10767	were	_
52-11	10768-10775	modeled	_
52-12	10776-10778	as	_
52-13	10779-10789	parametric	_
52-14	10790-10800	regressors	_
52-15	10801-10805	onto	_
52-16	10806-10814	separate	_
52-17	10815-10817	δ+	_
52-18	10818-10821	and	_
52-19	10822-10824	δ-	_
52-20	10825-10832	outcome	_
52-21	10833-10839	events	_
52-22	10840-10841	,	_
52-23	10842-10854	respectively	_
52-24	10855-10856	.	_

53-1	10857-10864	Effects	_
53-2	10865-10868	due	_
53-3	10869-10871	to	_
53-4	10872-10875	run	_
53-5	10876-10882	number	_
53-6	10883-10884	,	_
53-7	10885-10889	time	_
53-8	10890-10892	in	_
53-9	10893-10900	scanner	_
53-10	10901-10902	,	_
53-11	10903-10906	and	_
53-12	10907-10911	head	_
53-13	10912-10920	movement	_
53-14	10921-10931	parameters	_
53-15	10932-10936	were	_
53-16	10937-10944	modeled	_
53-17	10945-10948	out	_
53-18	10949-10951	as	_
53-19	10952-10960	nuisance	_
53-20	10961-10971	covariates	_
53-21	10972-10975	for	_
53-22	10976-10980	each	_
53-23	10981-10985	time	_
53-24	10986-10991	point	_
53-25	10992-10993	.	_

54-1	10994-11000	Within	_
54-2	11001-11004	and	_
54-3	11005-11011	paired	_
54-4	11012-11022	drug-state	_
54-5	11023-11031	analyses	_
54-6	11032-11033	.	_

55-1	11034-11037	The	_
55-2	11038-11049	within-drug	_
55-3	11050-11055	state	_
55-4	11056-11057	(	_
55-5	11058-11060	C-	_
55-6	11061-11064	and	_
55-7	11065-11067	C+	_
55-8	11068-11069	,	_
55-9	11070-11082	respectively	_
55-10	11083-11084	)	_
55-11	11085-11088	and	_
55-12	11089-11104	paired-subjects	_
55-13	11105-11106	(	_
55-14	11107-11109	C-	_
55-15	11110-11111	>	_
55-16	11112-11114	C+	_
55-17	11115-11116	)	_
55-18	11117-11124	effects	_
55-19	11125-11127	of	_
55-20	11128-11135	cocaine	_
55-21	11136-11139	use	_
55-22	11140-11144	were	_
55-23	11145-11153	compared	_
55-24	11154-11159	using	_
55-25	11160-11170	one-sample	_
55-26	11171-11174	and	_
55-27	11175-11181	paired	_
55-28	11182-11190	subjects	_
55-29	11191-11192	’	_
55-30	11193-11199	second	_
55-31	11200-11205	level	_
55-32	11206-11215	contrasts	_
55-33	11216-11218	in	_
55-34	11219-11223	SPM8	_
55-35	11224-11225	.	_

56-1	11226-11229	The	_
56-2	11230-11237	effects	_
56-3	11238-11240	of	_
56-4	11241-11249	interest	_
56-5	11250-11254	were	_
56-6	11255-11261	neural	_
56-7	11262-11271	responses	_
56-8	11272-11274	to	_
56-9	11275-11277	δ+	_
56-10	11278-11281	and	_
56-11	11282-11284	δ−	_
56-12	11285-11286	.	_

57-1	11287-11289	In	_
57-2	11290-11294	line	_
57-3	11295-11299	with	_
57-4	11300-11308	previous	_
57-5	11309-11313	data	_
57-6	11314-11327	demonstrating	_
57-7	11328-11331	the	_
57-8	11332-11336	role	_
57-9	11337-11339	of	_
57-10	11340-11348	striatum	_
57-11	11349-11352	and	_
57-12	11353-11355	DA	_
57-13	11356-11358	in	_
57-14	11359-11367	learning	_
57-15	11368-11369	,	_
57-16	11370-11373	the	_
57-17	11374-11381	imaging	_
57-18	11382-11390	analyses	_
57-19	11391-11395	were	_
57-20	11396-11402	masked	_
57-21	11403-11406	for	_
57-22	11407-11410	the	_
57-23	11411-11419	striatum	_
57-24	11420-11421	.	_

58-1	11422-11432	Anatomical	_
58-2	11433-11438	masks	_
58-3	11439-11443	were	_
58-4	11444-11455	constructed	_
58-5	11456-11461	using	_
58-6	11462-11475	WFU-pickatlas	_
58-7	11476-11485	including	_
58-8	11486-11489	the	_
58-9	11490-11500	structures	_
58-10	11501-11503	of	_
58-11	11504-11507	the	_
58-12	11508-11515	caudate	_
58-13	11516-11517	,	_
58-14	11518-11525	putamen	_
58-15	11526-11527	,	_
58-16	11528-11531	and	_
58-17	11532-11538	globus	_
58-18	11539-11547	pallidus	_
58-19	11548-11549	.	_

59-1	11550-11554	Also	_
59-2	11555-11563	included	_
59-3	11564-11566	in	_
59-4	11567-11570	the	_
59-5	11571-11579	striatum	_
59-6	11580-11584	mask	_
59-7	11585-11588	was	_
59-8	11589-11592	the	_
59-9	11593-11600	nucleus	_
59-10	11601-11610	accumbens	_
59-11	11611-11612	(	_
59-12	11613-11616	per	_
59-13	11617-11625	Garrison	_
59-14	11626-11628	et	_
59-15	11629-11632	al.	_
59-16	11633-11634	,	_
59-17	11635-11636	)	_
59-18	11637-11638	.	_

60-1	11639-11646	Results	_
60-2	11647-11651	were	_
60-3	11652-11663	thresholded	_
60-4	11664-11668	with	_
60-5	11669-11670	a	_
60-6	11671-11676	voxel	_
60-7	11677-11682	level	_
60-8	11683-11694	uncorrected	_
60-9	11695-11696	p	_
60-10	11697-11698	<	_
60-11	11699-11704	0.001	_
60-12	11705-11706	,	_
60-13	11707-11713	unless	_
60-14	11714-11719	noted	_
60-15	11720-11721	,	_
60-16	11722-11725	and	_
60-17	11726-11737	significant	_
60-18	11738-11746	clusters	_
60-19	11747-11751	were	_
60-20	11752-11759	defined	_
60-21	11760-11765	using	_
60-22	11766-11783	family-wise-error	_
60-23	11784-11794	correction	_
60-24	11795-11796	.	_

61-1	11797-11808	Correlation	_
61-2	11809-11817	analyses	_
61-3	11818-11825	between	_
61-4	11826-11839	cocaine-state	_
61-5	11840-11849	modulated	_
61-6	11850-11858	learning	_
61-7	11859-11863	rate	_
61-8	11864-11867	and	_
61-9	11868-11874	neural	_
61-10	11875-11885	prediction	_
61-11	11886-11891	error	_
61-12	11892-11899	signals	_
61-13	11900-11901	.	_

62-1	11902-11904	To	_
62-2	11905-11911	relate	_
62-3	11912-11922	drug-state	_
62-4	11923-11930	effects	_
62-5	11931-11933	on	_
62-6	11934-11944	behavioral	_
62-7	11945-11953	learning	_
62-8	11954-11959	rates	_
62-9	11960-11961	(	_
62-10	11962-11964	α+	_
62-11	11965-11968	and	_
62-12	11969-11971	α-	_
62-13	11972-11973	)	_
62-14	11974-11978	with	_
62-15	11979-11982	the	_
62-16	11983-11996	corresponding	_
62-17	11997-12003	neural	_
62-18	12004-12005	δ	_
62-19	12006-12013	signals	_
62-20	12014-12015	,	_
62-21	12016-12024	separate	_
62-22	12025-12030	first	_
62-23	12031-12036	level	_
62-24	12037-12040	and	_
62-25	12041-12047	second	_
62-26	12048-12053	level	_
62-27	12054-12058	GLMs	_
62-28	12059-12063	were	_
62-29	12064-12071	created	_
62-30	12072-12074	to	_
62-31	12075-12084	correlate	_
62-32	12085-12099	within-subject	_
62-33	12100-12114	drug-modulated	_
62-34	12115-12117	α+	_
62-35	12118-12121	and	_
62-36	12122-12124	α-	_
62-37	12125-12136	differences	_
62-38	12137-12138	(	_
62-39	12139-12141	C-	_
62-40	12142-12143	>	_
62-41	12144-12146	C+	_
62-42	12147-12150	for	_
62-43	12151-12153	α+	_
62-44	12154-12157	and	_
62-45	12158-12160	C-	_
62-46	12161-12162	>	_
62-47	12163-12165	C+	_
62-48	12166-12169	for	_
62-49	12170-12172	δ-	_
62-50	12173-12174	,	_
62-51	12175-12187	respectively	_
62-52	12188-12189	)	_
62-53	12190-12194	with	_
62-54	12195-12198	the	_
62-55	12199-12212	corresponding	_
62-56	12213-12219	neural	_
62-57	12220-12231	differences	_
62-58	12232-12235	for	_
62-59	12236-12244	positive	_
62-60	12245-12248	and	_
62-61	12249-12257	negative	_
62-62	12258-12259	δ	_
62-63	12260-12261	,	_
62-64	12262-12274	respectively	_
62-65	12275-12276	(	_
62-66	12277-12279	C-	_
62-67	12280-12281	>	_
62-68	12282-12284	C+	_
62-69	12285-12288	for	_
62-70	12289-12291	δ+	_
62-71	12292-12295	and	_
62-72	12296-12298	C-	_
62-73	12299-12300	>	_
62-74	12301-12303	C+	_
62-75	12304-12307	for	_
62-76	12308-12310	δ-	_
62-77	12311-12312	,	_
62-78	12313-12325	respectively	_
62-79	12326-12327	)	_
62-80	12328-12329	.	_

63-1	12330-12337	Results	_
63-2	12338-12342	were	_
63-3	12343-12348	again	_
63-4	12349-12360	thresholded	_
63-5	12361-12365	with	_
63-6	12366-12367	a	_
63-7	12368-12373	voxel	_
63-8	12374-12379	level	_
63-9	12380-12391	uncorrected	_
63-10	12392-12393	p	_
63-11	12394-12395	<	_
63-12	12396-12401	0.001	_
63-13	12402-12403	,	_
63-14	12404-12407	and	_
63-15	12408-12419	significant	_
63-16	12420-12428	clusters	_
63-17	12429-12433	were	_
63-18	12434-12441	defined	_
63-19	12442-12447	using	_
63-20	12448-12455	family-	_
63-21	12456-12466	wise-error	_
63-22	12467-12477	correction	_
63-23	12478-12479	.	_

64-1	12480-12482	In	_
64-2	12483-12491	addition	_
64-3	12492-12493	,	_
64-4	12494-12507	leave-one-out	_
64-5	12508-12524	cross-validation	_
64-6	12525-12533	analyses	_
64-7	12534-12538	were	_
64-8	12539-12548	performed	_
64-9	12549-12551	in	_
64-10	12552-12559	regions	_
64-11	12560-12562	of	_
64-12	12563-12571	interest	_
64-13	12572-12573	(	_
64-14	12574-12577	see	_
64-15	12578-12590	Supplemental	_
64-16	12591-12598	Methods	_
64-17	12599-12600	)	_
64-18	12601-12603	to	_
64-19	12604-12610	reduce	_
64-20	12611-12615	bias	_
64-21	12616-12619	due	_
64-22	12620-12622	to	_
64-23	12623-12639	non-independence	_
64-24	12640-12641	.	_

65-1	12642-12655	Relationships	_
65-2	12656-12663	between	_
65-3	12664-12670	neural	_
65-4	12671-12681	prediction	_
65-5	12682-12687	error	_
65-6	12688-12697	responses	_
65-7	12698-12701	and	_
65-8	12702-12712	behavioral	_
65-9	12713-12720	cocaine	_
65-10	12721-12724	use	_
65-11	12725-12733	measures	_
65-12	12734-12735	.	_

66-1	12736-12738	To	_
66-2	12739-12743	test	_
66-3	12744-12757	relationships	_
66-4	12758-12765	between	_
66-5	12766-12769	the	_
66-6	12770-12778	observed	_
66-7	12779-12785	neural	_
66-8	12786-12794	learning	_
66-9	12795-12802	signals	_
66-10	12803-12806	and	_
66-11	12807-12814	cocaine	_
66-12	12815-12818	use	_
66-13	12819-12827	measures	_
66-14	12828-12829	,	_
66-15	12830-12843	questionnaire	_
66-16	12844-12848	data	_
66-17	12849-12863	characterizing	_
66-18	12864-12874	individual	_
66-19	12875-12879	drug	_
66-20	12880-12883	use	_
66-21	12884-12891	history	_
66-22	12892-12895	and	_
66-23	12896-12903	current	_
66-24	12904-12911	cocaine	_
66-25	12912-12919	craving	_
66-26	12920-12924	were	_
66-27	12925-12931	tested	_
66-28	12932-12939	against	_
66-29	12940-12948	subjects	_
66-30	12949-12950	’	_
66-31	12951-12953	C-	_
66-32	12954-12960	neural	_
66-33	12961-12971	prediction	_
66-34	12972-12977	error	_
66-35	12978-12987	responses	_
66-36	12988-12989	(	_
66-37	12990-12995	given	_
66-38	12996-12999	the	_
66-39	13000-13007	primary	_
66-40	13008-13015	results	_
66-41	13016-13018	of	_
66-42	13019-13027	interest	_
66-43	13028-13037	involving	_
66-44	13038-13046	enhanced	_
66-45	13047-13049	δ+	_
66-46	13050-13054	from	_
66-47	13055-13059	drug	_
66-48	13060-13071	deprivation	_
66-49	13072-13073	)	_
66-50	13074-13075	.	_

67-1	13076-13081	Again	_
67-2	13082-13083	,	_
67-3	13084-13089	using	_
67-4	13090-13103	leave-one-out	_
67-5	13104-13120	cross-validation	_
67-6	13121-13129	analysis	_
67-7	13130-13131	,	_
67-8	13132-13138	neural	_
67-9	13139-13146	signals	_
67-10	13147-13151	from	_
67-11	13152-13158	trials	_
67-12	13159-13163	with	_
67-13	13164-13166	δ+	_
67-14	13167-13171	were	_
67-15	13172-13182	correlated	_
67-16	13183-13187	with	_
67-17	13188-13193	years	_
67-18	13194-13196	of	_
67-19	13197-13201	drug	_
67-20	13202-13205	use	_
67-21	13206-13209	and	_
67-22	13210-13219	subscales	_
67-23	13220-13222	of	_
67-24	13223-13226	the	_
67-25	13227-13234	Cocaine	_
67-26	13235-13242	Craving	_
67-27	13243-13256	Questionnaire	_
67-28	13257-13258	.	_

68-1	13259-13262	The	_
68-2	13263-13271	analyses	_
68-3	13272-13282	identified	_
68-4	13283-13296	relationships	_
68-5	13297-13302	among	_
68-6	13303-13308	years	_
68-7	13309-13311	of	_
68-8	13312-13316	drug	_
68-9	13317-13320	use	_
68-10	13321-13322	,	_
68-11	13323-13325	δ+	_
68-12	13326-13332	neural	_
68-13	13333-13339	signal	_
68-14	13340-13341	,	_
68-15	13342-13345	and	_
68-16	13346-13349	the	_
68-17	13350-13356	desire	_
68-18	13357-13359	to	_
68-19	13360-13363	use	_
68-20	13364-13371	cocaine	_
68-21	13372-13373	.	_

69-1	13374-13379	Based	_
69-2	13380-13382	on	_
69-3	13383-13386	the	_
69-4	13387-13394	results	_
69-5	13395-13397	of	_
69-6	13398-13401	the	_
69-7	13402-13413	correlation	_
69-8	13414-13422	analysis	_
69-9	13423-13424	,	_
69-10	13425-13426	a	_
69-11	13427-13436	mediation	_
69-12	13437-13445	analysis	_
69-13	13446-13449	was	_
69-14	13450-13459	performed	_
69-15	13460-13467	testing	_
69-16	13468-13475	whether	_
69-17	13476-13482	neural	_
69-18	13483-13491	learning	_
69-19	13492-13499	signals	_
69-20	13500-13508	mediated	_
69-21	13509-13512	the	_
69-22	13513-13525	relationship	_
69-23	13526-13533	between	_
69-24	13534-13542	duration	_
69-25	13543-13545	of	_
69-26	13546-13550	drug	_
69-27	13551-13554	use	_
69-28	13555-13558	and	_
69-29	13559-13570	individuals	_
69-30	13571-13572	’	_
69-31	13573-13579	desire	_
69-32	13580-13582	to	_
69-33	13583-13586	use	_
69-34	13587-13594	cocaine	_
69-35	13595-13597	or	_
69-36	13598-13606	expected	_
69-37	13607-13615	positive	_
69-38	13616-13623	outcome	_
69-39	13624-13628	from	_
69-40	13629-13636	cocaine	_
69-41	13637-13640	use	_
69-42	13641-13642	(	_
69-43	13643-13645	C-	_
69-44	13646-13654	measures	_
69-45	13655-13656	)	_
69-46	13657-13658	.	_

70-1	13659-13660	A	_
70-2	13661-13670	bootstrap	_
70-3	13671-13679	approach	_
70-4	13680-13682	to	_
70-5	13683-13692	mediation	_
70-6	13693-13696	was	_
70-7	13697-13708	implemented	_
70-8	13709-13711	in	_
70-9	13712-13713	R	_
70-10	13714-13716	to	_
70-11	13717-13726	calculate	_
70-12	13727-13728	a	_
70-13	13729-13731	95	_
70-14	13732-13733	%	_
70-15	13734-13744	confidence	_
70-16	13745-13753	interval	_
70-17	13754-13758	with	_
70-18	13759-13765	10,000	_
70-19	13766-13778	bootstrapped	_
70-20	13779-13788	resamples	_
70-21	13789-13790	.	_

